Core Viewpoint - The approval of the innovative drug Rilaforp α injection by the National Medical Products Administration marks a significant advancement in the treatment of advanced gastric cancer, addressing a critical need in the market [1] Company Summary - The company, through its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd., has developed Rilaforp α injection, a dual-function fusion protein targeting PD-L1 and TGF-βRII, which is expected to improve treatment outcomes for patients with advanced gastric cancer [1] - The total research and development investment for the Rilaforp α injection project has reached approximately 71.13 million yuan [1] Industry Summary - Gastric cancer has nearly one million new cases globally each year, with over 655,000 deaths, highlighting the severity of the disease and the urgent need for effective treatment options [1] - Current immunotherapy options, particularly immune checkpoint inhibitors, have shown limited long-term survival benefits for patients, especially those with liver metastases, indicating a gap in the market for innovative therapies [1]